FDA approves oral semaglutide pill

The U.S. Food and Drug Administration has cleared Novo Nordisk's oral semaglutide for chronic weight management, making it the first GLP-1 pill approved for weight loss in the United States. The approval adds a tablet form of Wegovy to a market that has been dominated by weekly injections. Novo Nordisk has said it expects a U.S. launch in early January 2026, with manufacturing underway in North Carolina. The label also includes use to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. ### Which product did the FDA approve, exactly? The FDA-approved label identifies the product as Wegovy tablet 25 mg, taken once daily. The approval covers adults with obesity, or adults with overweight who have at least one weight-related condition, according to the prescribing information. The accessdata.fda.gov label shows the tablet is also approved to reduce the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight. That mirrors a broader push by drugmakers to position obesity drugs beyond weight reduction alone. ### What did the main trial show? Novo Nordisk based the filing in part on the phase 3 OASIS 4 trial, a 64-week study in 307 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes. The company said patients taking oral semaglutide 25 mg achieved 13.6% average weight loss in the treatment-policy analysis, compared with about 2.4% for placebo. The same trial showed 16.6% average weight loss in an analysis assuming patients remained on treatment, versus 2.7% for placebo, according to Novo Nordisk's approval announcement and trial materials. ClinicalTrials.gov lists OASIS 4 as completed, with Novo Nordisk as sponsor. ### Why does the pill matter to patients and prescribers? CNBC reported in April that Novo Nordisk's U.S. launch of the Wegovy pill was drawing in patients who had not previously started GLP-1 treatment, citing interviews with obesity specialists and patients. A tablet can appeal to people who do not want injections, though coverage, price and tolerability still shape access. Novo Nordisk executive Emil Kongshøj Larsen told CNBC on May 18 that the company planned to go "all in" on launches outside the United States later in 2026, pending approvals. He said the U.S. launch had been strong and that Novo expected to replicate that in other markets. ### How does this stack up against rivals? Eli Lilly is also developing oral obesity medicines, including orforglipron, as large drugmakers race to offer easier-to-use alternatives to injections. Novo Nordisk's approval gives it the first FDA-cleared oral GLP-1 specifically for weight loss, but not the field to itself. Novo Nordisk has also pointed to comparative analyses suggesting its pill can compete on efficacy and discontinuation rates, though head-to-head studies with Lilly's candidates are limited. For now, the clearest verified benchmark is the approved Wegovy tablet label and the OASIS 4 data supporting it. ### What happens next? January 2026 is Novo Nordisk's stated U.S. launch target for Wegovy tablet, according to the company's approval announcement. Outside the United States, the company told CNBC it expects the first additional launches later in 2026, subject to regulatory decisions in those markets. Novo Nordisk's U.S. news archive shows the company has continued expanding its obesity portfolio in 2026, including higher-dose injectable Wegovy and broader access programs. The next concrete milestone for the pill is commercial rollout, with U.S. supply and payer coverage likely to determine how quickly the tablet moves beyond an approval into routine prescribing.